Dianthus Therapeutics Q3 2026 Results: Net Loss of $46.6M, Loss Widens
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing product candidates such as claseprubart, DNTH212, and DNTH312. As of November 2, 2026, the company reported 56,312,712 shares of common stock outstanding and is classified as a non-accelerated filer and smaller reporting company.
- Key figure
- Net loss $46.6M